News
Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...
Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.
America’s new approach to enforcing a decades-old law outlawing foreign bribery means fresh risk for Canadian multinationals, ...
Williams County Public Library will hold a retirement reception in honor of Stryker Library Assistant Linda Woodall.
2d
The Manila Times on MSNHaliburton warns Pacers of 'poison' of outside noise before Game 7Indiana star Tyrese Haliburton says the Pacers must keep their focus firmly on the Oklahoma City Thunder and block out the ...
Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company ...
WDVM Hagerstown on MSN3d
Virginia man convicted of a hate crimeA Virginia man was convicted of a hate crime in Thornburg. Ice’s ‘inhumane’ arrest of well-known vineyard manager shakes ...
Stryker stock ended Monday with a flatline finish, but the day itself was anything but boring. The price action played out ...
Investing.com -- Moody’s Ratings upgraded Stryker Corporation (NYSE: SYK )’s senior unsecured notes to A3 from Baa1 on Wednesday, while revising the company’s outlook to stable from positive.
The ROBO Global Healthcare Technology & Innovation Index offers unique, targeted exposure to innovators. Click to read.
Stryker stock started the week limping, gapping down at the open and slipping to a low of $373.36 before showing a mild ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results